Neurology & Brain Disorders Clinical Trials Update: Week 15, 2026

Published April 10, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

This Phase 3 study by Hoffmann-La Roche is exploring a new way to screen people for eligibility in Alzheimer's disease trials. By using simple tests such as blood samples and cognitive assessments, the study aims to find individuals who could benefit from participating in future Alzheimer's treatment research. This could help speed up the development of new therapies by matching the right participants to the right studies more efficiently.

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Sponsored by Novo Nordisk, this Phase 3 trial is testing the oral medication semaglutide in people with early-stage Alzheimer's disease. The goal is to see if semaglutide can slow down memory loss and thinking problems during the early phases of the condition. The study lasted about three years, and results are expected soon, which may open new treatment options for those affected.

Reduce Loneliness in Care Partners of Persons With AD/ADRD

This completed study from Northwell Health evaluated a web-based therapy program designed to reduce feelings of loneliness in caregivers of people with Alzheimer's and related dementias. Caregivers often experience isolation, and this approach could offer an accessible way to support their emotional health. The results, expected soon, may provide new tools to help caregivers feel more connected and supported.

Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill

Noah Pharmaceuticals conducted this Phase 2 trial testing a combination pill for managing Alzheimer's disease symptoms. The study looked at whether this mix of drugs could improve thinking abilities and daily functioning. With 121 participants aged 50 to 85, the findings could help guide the development of simpler treatment options that address multiple aspects of the disease.

Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)

This Canadian study is exploring a non-drug approach combining brain stimulation and cognitive training to slow memory loss in older adults with mild cognitive impairment or depression. By targeting early changes in thinking skills, this intervention aims to delay the progression to Alzheimer's dementia. The trial is ongoing and may offer new ways to protect brain health without medications.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.